TuHURA Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, TuHURA Biosciences sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
TuHURA Biosciences: 5 sponsored US clinical trials, 2 recruiting.
TuHURA Biosciences sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Or Metastatic Merkel Cell Carcinoma, with 2 trials.
Upper-quartile sponsor footprint
TuHURA Biosciences sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
NCT06940440
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
NCT06947928
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
NCT04925713
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
NCT04160065
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
NCT03655756
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the TuHURA Biosciences pipeline
2 recruiting of 5 indexed (40% open); 3 completed (60%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Advanced Or Metastatic Merkel Cell Carcinoma (2 trials), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
TuHURA Biosciences: open-pipeline peers nationwide
Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
TuHURA Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this TuHURA Biosciences page
5 registered trials is a research-attention snapshot, not an endorsement of TuHURA Biosciences or any single study.
- 2 of TuHURA Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Or Metastatic Merkel Cell Carcinoma is the condition TuHURA Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Or Metastatic Merkel Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. TuHURA Biosciences pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.